BioWorld Asia

Oct. 6, 2010

One GIANT Step for Mankind: New Genes for Height Control

Agennix Nets $105M in Share Offer to Develop Talactoferrin

GW Testing Cannabinoids in Diabetes, Metabolic Syndrome

'Father of 4 Million' Wins Medicine Nobel for IVF Work

Other News To Note

Zealand's Lixisenatide Hits Mark in Phase III Combo Trial

Lixisenatide, the Type II diabetes molecule discovered by Zealand Pharma A/S, met the primary endpoint in the first Phase III combination trial. (BioWorld International) Read More

GlaxoSmithKline Spins Out Firm with Ion Channel Portfolio

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Fauci’s silence may put him in contempt of Congress

BioWorld

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...